☰

Rabia A. Gilani, Ph.D. - Publications

Affiliations: 
2011 Toxicology University of Maryland School of Medicine, Baltimore, MD, United States 
Area:
Molecular Biology, Biochemistry
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Gilani RA, Phadke S, Bao LW, Lachacz EJ, Dziubinski ML, Brandvold KR, Steffey ME, Kwarcinski FE, Graveel CR, Kidwell KM, Merajver SD, Soellner MB. Retraction: UM-164: A Potent c-Src/p38 Kinase Inhibitor with Activity against Triple-Negative Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 26: 1777. PMID 32238414 DOI: 10.1158/1078-0432.CCR-20-0653  0.37
2018 Kaushal N, Tiruchinapally G, Durmaz YY, Bao L, Gilani R, Merajver SD, ElSayed MEH. Synergistic inhibition of aggressive breast cancer cell migration and invasion by cytoplasmic delivery of anti-RhoC silencing RNA and presentation of EPPT1 peptide on "smart" particles. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 30149048 DOI: 10.1016/J.Jconrel.2018.07.042  0.417
2018 Jiagge E, Bensenhaver J, Celina K, Hoenerhoff M, Gilani R, Kyei I, Oppong J, Awuah B, Adjei E, Wicha M, Newman L, Merajver S. Creating Models to Identify New Therapeutic Options for Aggressive African Breast Cancers Journal of Global Oncology. 4: 206s-206s. DOI: 10.1200/Jgo.18.83500  0.458
2018 Gilani R, Lachacz E, Bao LW, Phadke S, Soellner M, Merajver S. Rational drug combination therapy for improved efficacy and delayed resistance in triple negative breast cancer. Journal of Clinical Oncology. 36: e13113-e13113. DOI: 10.1200/Jco.2018.36.15_Suppl.E13113  0.456
2018 Caceres S, Little AC, Yates JA, Gilani RA, Merajver SD. Abstract 2044: Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) modulates VEGF-C and VEGF-D secretion in the triple negative breast cancer cell line MDA-MB-231 Tumor Biology. DOI: 10.1158/1538-7445.Am2018-2044  0.431
2017 Gilani RA, Lachacz EJ, Phadke S, Bao LW, Cheng X, Jiagge EM, Soellner MB, Merajver SD. Abstract 4117: Mechanisms of acquired resistance to c-Src kinase inhibitor in triple negative breast cancer Cancer Research. 77: 4117-4117. DOI: 10.1158/1538-7445.Am2017-4117  0.522
2014 Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast Cancer Research : Bcr. 16: R15. PMID 24472707 DOI: 10.1186/Bcr3609  0.718
2013 Schech AJ, Kazi AA, Gilani RA, Brodie AH. Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB. Molecular Cancer Therapeutics. 12: 1356-66. PMID 23619300 DOI: 10.1158/1535-7163.Mct-12-0304  0.685
2013 Shah P, Sabnis GJ, Goloubeva O, Kazi A, Schech A, Gilani R, Gau Y, Chumsri S, Brodie A. Abstract 1311: Preclinical assessment of an HDAC inhibitor combined with a retinoid in AI resistant breast cancer. Cancer Research. 73: 1311-1311. DOI: 10.1158/1538-7445.Am2013-1311  0.724
2012 Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Research and Treatment. 135: 681-92. PMID 22878889 DOI: 10.1007/S10549-012-2148-8  0.734
2012 Gilani R, Kazi AA, Scheh A, Chumsri S, Shah P, Brodie A. Abstract 787: Involvement of HER2, HIF-1, and BCRP in cancer stem cell characteristics of letrozole-resistant breast cancer cells Cancer Research. 72: 787-787. DOI: 10.1158/1538-7445.Am2012-787  0.748
2011 Kazi AA, Gilani RA, Brodie AH. Abstract 2303: The potential role of nonhypoxic HIF-1 in HER2-mediated aromatase inhibitor resistant breast cancer Cancer Research. 71: 2303-2303. DOI: 10.1158/1538-7445.Am2011-2303  0.576
2011 Schech A, Gilani R, Kazi A, Brodie A. P1-02-02: Zoledronic Acid Reverses the Epithelial-Mesenchymal Transition While Inhibiting the Tumor Initiating Cell Population of Highly Tumorigenic Breast Cancer Cell Lines. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-02-02  0.733
2010 Sabnis G, Goloubeva O, Gilani R, Macedo L, Brodie A. Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment. Molecular Cancer Therapeutics. 9: 46-56. PMID 20053764 DOI: 10.1158/1535-7163.Mct-09-0696  0.662
2010 Kazi AA, Gilani RA, Sabnis GJ, Brodie AH. Abstract 4611: Growth inhibitory effects of lapatinib on letrozole resistant breast cancer cells via HER2-AIB1-ERα crosstalk Cancer Research. 70: 4611-4611. DOI: 10.1158/1538-7445.Am10-4611  0.658
2009 Sabnis G, Goloubeva O, Macedo L, Gilani R, Gediya L, Njar V, Brodie A. Combination of HDACi entinostat (SNDX-275) with letrozole provides control over tumor growth in MDA-MB-231 xenograft model. Cancer Research. 69: 6128. DOI: 10.1158/0008-5472.Sabcs-6128  0.575
2009 Sabnis G, Goloubeva O, Gilani R, Nguyen N, Chumsri S, Macedo L, Sukumar S, Brodie A. Expression of ERα and Aromatase in MDA-MB-231 Tumors by HDAC Inhibitor Entinostat Leads to Growth Inhibition by Aromatase Inhibitor Letrozole. Cancer Research. 69: 401-401. DOI: 10.1158/0008-5472.Sabcs-09-401  0.547
Show low-probability matches.